MFN2 and amyotrophic lateral sclerosis: The transgenic Mfn2 overexpression approach introduced a persistent intrinsic protective measure targeted to neurons, whereas small molecule mitofusin activation was a system-wide therapeutic initiated only after signs of ALS-linked neuromuscular degeneration emerged.